Cyclometalated iridium( iii ) complexes induce mitochondria-derived paraptotic cell death and inhibit tumor growth in vivo
The development of iridium complexes as potent anticancer agents has received increasing attention in recent years. In this study, four cyclometalated Ir( iii ) complexes with good photophysical properties and potent anticancer activity have been synthesized and characterized. They are taken up by h...
Saved in:
Published in | Dalton transactions : an international journal of inorganic chemistry Vol. 47; no. 20; pp. 6942 - 6953 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Royal Society of Chemistry
2018
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The development of iridium complexes as potent anticancer agents has received increasing attention in recent years. In this study, four cyclometalated Ir(
iii
) complexes with good photophysical properties and potent anticancer activity have been synthesized and characterized. They are taken up by human lung adenocarcinoma A549 cells very quickly and specifically target mitochondria. Mechanism studies reveal that one of them, namely
IrM2
, induces paraptosis accompanied by excessive mitochondria-derived cytoplasmic vacuoles. Meanwhile,
IrM2
affects the ubiquitin–proteasome system (UPS) and mitogen-activated protein kinase (MAPK) signaling pathways. Furthermore,
IrM2
rapidly induces a series of mitochondria-related dysfunctional events, including the loss of mitochondrial membrane potential, cellular ATP depletion, mitochondrial respiration inhibition and reactive oxygen species (ROS) elevation. The rapid loss of mitochondrial functions, elevation of ROS and impairment of the UPS induced by
IrM2
lead to the collapse of mitochondria and the subsequent cytoplasmic vacuolation before the cells are ready to start the mechanisms of apoptosis and/or autophagy. Among the ROS, superoxide anion radicals play a critical role in
IrM2
-mediated cell death.
In vivo
studies reveal that
IrM2
can significantly inhibit tumor growth in a mouse model. This work gives useful insights into the design and anticancer mechanisms of new metal-based anticancer agents. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ISSN: | 1477-9226 1477-9234 1477-9234 |
DOI: | 10.1039/C8DT00783G |